Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7199-7206

  Couch, Marion E ^a   Ferris, Robert L ^b,h   Brennan, Joseph A ^c   Koch, Wayne M ^d   Jaffee, Elizabeth M ^d   Leibowitz, Michael S ^b   Nepom, Gerald T ^e,f   Erlich, Henry A ^g   Sidransky, David ^d,i  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e BENAROYA RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g ROCHE MOLECULAR SYSTEMS   (United States)

^h Departments of Otolaryngology and Immunology   (United States)

ⁱ 6252 JHOC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA DQ ANTIGEN; HLA DQ7 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR1 ANTIGEN; MUTANT PROTEIN; PEPTIDE; PROTEIN ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HAPLOTYPE; HEAD AND NECK CANCER; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IN VITRO STUDY; MOLECULAR RECOGNITION; MOLECULE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; SEROLOGY; WILD TYPE;

AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; HEAD AND NECK NEOPLASMS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; TH2 CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37249006242     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0682     Document Type: Article

References (42)

1. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047-60.
2. Chada S, Mhashilkar A, Roth JA, Gabrilovich D. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel 2003;6:169-73.
3. Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005;23:5099-107.
4. Yanuck M, Carbone DP, Pendleton CD, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993;53:3257-61.
5. Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. EurJ Immunol 1993;23:2072-7.
6. Ropke M, Hald J, Guldberg P, et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A 1996;93:14704-7.
7. Sirianni N, Ha PK, Oelke M, et al. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:6929-37.
8. Pardoll DM. New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol1 993;5:719-25.
9. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
10. Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD, Jr. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res 2005;65:10059-67.
11. McCarter M, Clarke J, Richter D, Wilson C. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 2005;138:321-8.
12. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-28.
13. Bennouna J, Hildesheim A, Chikamatsu K, Gooding W, Storkus WJ, Whiteside TL. Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. J Immunol Methods 2002;261:145-56.
14. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
15. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43.
16. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003;97:682-9.
17. Sainger RN, Shah MH, Desai AA, et al. Clinical significance of serum p53 antibodies in oral cancer. Tumori 2006;92:134-9.
18. Saleh J, Brunner C, Golzer R, Nastainczyk W, Montenarh M. p53 autoantibodies from patients with head and neck cancer recognise common epitopes on the polypeptide chain of p53. Cancer Lett 2006;233:48-56.
19. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
20. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992;89:3439-42.
21. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 1994;54:3752-7.
22. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
23. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
24. Ruppert JM, Stillman B. Analysis of a protein-binding domain of p53. Mol Cell Biol 1993;13:3811-20.
25. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-62.
26. Kwok WW, Nepom GT, Raymond FC. HLA-DQ polymorphisms are highly selective for peptide binding interactions. J Immunol 1995;155:2468-76.
27. Mailliard RB W-KA, Cai Q, Wesa A, et al. α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-7.
28. Hathaway B, Landsittel DP, Gooding W, et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 2005;115:522-7.
29. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16:102-7.
30. Parham PBC, Bodmer WF. Use of a monoclonal antibody (W6/32) in structuralstu dies of HLA-A,B,C, antigens. J Immunol 1979;123:342-9.
31. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 1993;161:239-56.
32. Fal kK, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Pools equencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994;39:230-42.
33. Chikamatsu K, Albers A, Stanson J, et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003;63:3675-81.
34. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
35. Marxsen J, Schmiegel W, Roder C, et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994;70:1031-4.
36. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
37. Angelopoulou K, Stratis M, Diamandis EP. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 1997;70:46-51.
38. Kaur J, Srivastava A, Ralhan R. Serum p53 antibodies in patients with orall esions: correlation with p53/HSP70 complexes. Int J Cancer 1997;74:609-13.
39. Bourhis J, Lubin R, Roche B, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1228-33.
40. Lubin R, Schlichtholz B, Bengoufa D, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993;53:5872-6.
41. Schlichtholz B, LegrosY, Gillet D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
42. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76:287-99.